Immunotech Biopharm Ltd
HKSE: 6978.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jian Zhang
- Employees
- 154
- Headquarters
- Beijing, China
- IPO year
- 2020
- Market cap
- HK$446.7M
- Website
- https://www.eaal.net
Loading 6978…
Loading profile data…Frequently asked questions about 6978
What does Immunotech Biopharm Ltd (6978.HK) do?
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for th...
Where does 6978.HK trade?
Immunotech Biopharm Ltd (6978.HK) trades on the Hong Kong Stock Exchange.
What sector is 6978.HK in?
Immunotech Biopharm Ltd (6978.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunotech Biopharm Ltd?
Jian Zhang is the chief executive officer of Immunotech Biopharm Ltd (6978.HK).
Where is Immunotech Biopharm Ltd headquartered?
Immunotech Biopharm Ltd is headquartered in China.
Does 6978.HK pay a dividend?
Immunotech Biopharm Ltd (6978.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6978.HK go public?
Immunotech Biopharm Ltd (6978.HK) completed its initial public offering in 2020.